Market Alert: ASX200 at Critical Support – Reversal or Further Fall?
Memphasys Limited (ASX: MEM) has completed its pivotal clinical trial for the Felix System, confirming its superior performance in sperm selection for Assisted Reproductive Technology. In partnership with Monash IVF, the study validated that the Felix System is statistically superior to Density Gradient Centrifugation and non-inferior to the Swim-Up technique in embryo utilization rates, a key ART benchmark. The system was significantly faster than both traditional methods, providing efficiency benefits, and was preferred by 100% of users over DGC and by more than half over Swim-Up.
With no reported adverse events, Memphasys is now preparing regulatory submissions for CE Mark (Europe), TGA (Australia), and CDSCO (India) while expanding commercial partnerships. Existing distribution agreements in Japan, Canada, and New Zealand, along with an LOI in China, position the company for rapid market expansion. As adoption increases, the Felix System is set to become a leading innovation in sperm separation technology.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 15, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
